Skip to main content
Home > BioCentury on BioBusiness > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Figure: Courting cancer

    Two heads are better Courting cancer The early stage deals completed by Novartis AG (NYSE:NVS; SIX:NOVN) since 2013 show the pharma has largely focused its pipeline building efforts in the two therapeutic areas of…

    Published on 5/23/2016
  • Figure: Novartis Executive Committee

    Two heads are better Novartis Executive Committee

    Published on 5/23/2016
  • Figure: Splitting for focus

    Two heads are better Splitting for focus Novartis AG (NYSE:NVS; SIX:NOVN) will split its innovative drug development division into two business units: Novartis Oncology and Novartis Pharmaceuticals. The oncology …

    Published on 5/23/2016
  • Two heads are better

    What Novartis needs to do beyond reorganization to grow innovation

    Novartis' new oncology unit appears to be set up for growth, but the pharmaceuticals unit may need more deals to stock its pipeline.

    Published on 5/23/2016
  • Figure: Capital rationing

    Global ambitions Capital rationing Last year, the average raised per private European company increased by 47% to $22.2 million from $15.1 million in 2014, helped by a few companies that secured significant funds.…

    Published on 5/16/2016
  • Figure: Clinical rationing

    Global ambitions Clinical rationing The total raised by private and public European biotechs with lead programs in clinical development rose by 42% to $4.7 billion in 2015 from $3.3 billion in 2014. The increase …

    Published on 5/16/2016
  • Figure: Competition for capital

    Global ambitions Competition for capital Total funding continued to increase in the U.S. and the EU, but European-domiciled companies continued to receive a modest share of the total. Last year, the money raised …

    Published on 5/16/2016
  • Figure: Hallmarks of ambition

    Global ambitions Hallmarks of ambition The 15 U.S. VCs who invested in the greatest number of rounds worldwide during 2010-15 put their money to work in Europe in innovative companies with ambitious pipelines, …

    Published on 5/16/2016
  • Figure: Missed opportunity

    Global ambitions Missed opportunity Between the start of 2013 and mid-2015, U.S. biotech share prices grew at nearly twice the rate of their European counterparts. But even as U.S. investors began to complain that…

    Published on 5/16/2016
  • Figure: Private financings

    Global ambitions Private financings The average money raised by private European biotechs increased by 47% to $22.2 million in 2015 vs. $15.1 million in 2014; however, the amount still lags the $32 million average…

    Published on 5/16/2016
  • Figure: Public financings

    Global ambitions Public financings The top figure shows that the amount raised via equity financings by public European biotechs rose 1.7x to $8.1 billion in 2015 vs. a 1.4x increase in the U.S. to $24.3 billion. …

    Published on 5/16/2016
  • Figure: U.S. investors close the gap

    Global ambitions U.S. investors close the gap European-domiciled public companies that attracted U.S. investors through a U.S. listing raised nearly as much on average as public companies domiciled in the U.S. The…

    Published on 5/16/2016
  • Figure: U.S. VCs stepping up

    Global ambitions U.S. VCs stepping up The 15 U.S. VCs who invested in the greatest number of rounds worldwide during 2010-15 drove up the average round size compared with all European rounds. The average round for…

    Published on 5/16/2016
  • Table: New funds

    Global ambitions New funds Since the start of 2015, at least 31 life science funds with a European presence are raising or have raised a total of more than $8 billion. Funds are listed in descending order by size.…

    Published on 5/16/2016
  • Table: U.S. investment in top rounds

    Global ambitions U.S. investment in top rounds U.S. investors participated in at least seven of 10 European venture equity financings of $80 million or more since the start of 2015. Firms with headquarters in the U.…

    Published on 5/16/2016
  • Global ambitions

    Why European biotechs should start courting U.S. capital now

    European biotechs with the drive to compete on a global scale should start courting U.S. investors now, before the U.S. markets heat back up.

    Published on 5/16/2016
  • Table: Bugs as drugs

    Community organizers Bugs as drugs Selected companies developing pharmaceutical products that contain microbes as the active moiety. Excludes bacterial cancer vaccines, bacteriophages and bacteria engineered to …

    Published on 5/9/2016
  • Table: Traditional drugs from bugs

    Community organizers Traditional drugs from bugs Selected companies developing traditional drug therapeutics based on insights obtained from studying the microbiome. Excludes antibiotics and compounds that inhibit…

    Published on 5/9/2016
  • Getting into the game

    How pharmas are thinking about the microbiome for drug development

    A handful of pharmas are developing microbiome-targeted therapies; more are mining it for new targets and diagnostic insights.

    Published on 5/9/2016
  • Community organizers

    How studying bacteria by function is reshaping microbiome therapies

    The next wave of microbiome companies is opening up new mechanisms to treat disease by targeting or mimicking bacterial functions.

    Published on 5/9/2016
  • Figure: N = 1

    Don't skip DMD patients N = 1 Billy Ellsworth, one of the DMD patients who participated in the trial of Sarepta's eteplirsen, and CDER Director Janet Woodcock at the April 25 advisory committee meeting for …

    Published on 5/2/2016
  • Just to confirm

    How Sarepta's eteplirsen confirmatory trials could support full approval

    Sarepta's planned eteplirsen confirmatory studies could generate evidence to support full approval without exposing exon-51 patients to placebo.

    Published on 5/2/2016
  • Box: Few ripples

    Just to confirm Few ripples Accelerated approval of eteplirsen from Sarepta Therapeutics Inc. would be unlikely to greatly complicate development of other DMD treatments. Summit Therapeutics plc CEO Glyn Edwards …

    Published on 5/2/2016
  • Don't skip DMD patients

    Why FDA should grant accelerated approval to eteplirsen for DMD

    Eteplirsen should receive accelerated approval for DMD because patients have earned the right to make the risk-benefit decision.

    Published on 5/2/2016
  • Figure: PK picture

    Endangered TIGER? PK picture FDA's PK analysis of rociletinib from Clovis Oncology Inc. (NASDAQ:CLVS) found that increasing concentrations of the compound did not correlate with increases in objective response …

    Published on 4/25/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993